Guide-yakabatana mibvunzo · Pakati Nhanho

AI muDrug Safety uye Pharmacovigilance Quiz

Ongorora mishumo yakaipa-yechiitiko, kucherechedzwa kwechiratidzo uye yakamisikidzwa kukodha mune zvinodhaka-kuchengetedzwa kwekutarisa mafambiro ekushanda pane zvigadzirwa.

Nzira dzekutungamira dzinoenderanaAI Mukuchengetedza Mishonga Uye Pharmacovigilance
Mubvunzo 1 ye 8

Chii chinangwa chekutanga che pharmacovigilance?

Tarisa mubvunzo wese8 mibvunzo

Mhinduro uye tsananguro zvinoonekwa paunenge uchitora bvunzo.

  1. Chii chinangwa chekutanga che pharmacovigilance?
    • Kuona, kuongorora, nekudzivirira kukuvadzwa kubva kumishonga mushure mekunge yashandiswa
    • Kutengesa mishonga mitsva kuvarapi
    • Kuisa mutengo wekutengesa wemishonga
    • Kugadzira mapiritsi ekurongedza
  2. In the published n2c2 clinical NLP system, what information did the system extract from narrative notes?
    • Only patients’ handwritten signatures
    • Medication and adverse-event concepts and their relations
    • Only final regulatory decisions
    • Only medicine prices
  3. Chii chinoonesa disproportionality ongororo mumadhatabhesi ezviitiko zvakashata?
    • Musiyano wemutengo pakati pema brand negeneric drugs
    • Chipatara chipi chakaendesa mishumo yakawanda
    • Zviitiko zvezvinodhaka zviviri zvakashumwa kakawanda kupfuura mukana wenhamba ungafanotaura
    • Mazuva ekupera kwemishonga
  4. What is VigiBase, according to Uppsala Monitoring Centre?
    • A database of randomized clinical-trial efficacy results only
    • A list of confirmed causal side effects for every medicine
    • A commercial catalogue of approved drug prices
    • The WHO global database of reported adverse events for medicines and vaccines
  5. Chii chinonzi MedDRA chinoshandiswa mune pharmacovigilance mapaipi?
    • Izwi rezvokurapa rakamisikidzwa rekukodha maitiro uye mamiriro
    • Mucherechedzo wepakiti yemishonga
    • Iyo yekuronga app yevanachiremba
    • Mhando yeMRI scanner
  6. Which sequence does UMC describe in its signal-management process?
    • Diagnosis, prescription, dispensing, billing and discharge
    • Detection, validation, prioritisation, assessment and communication
    • Data collection, automatic causality decision, recall and litigation
    • Model training, deployment, billing and marketing
  7. How should a high disproportionality score in a spontaneous-report database be interpreted?
    • As a population incidence rate for all patients
    • As a confirmed causal adverse reaction
    • As a statistical signal for further assessment, not proof that the drug caused the event
    • As proof that no other factor contributed
  8. Which four elements satisfy the minimum ICSR criteria in ICH E2D(R1)?
    • A confirmed causal link, a batch number, a prescriber signature, and a laboratory result
    • A product label, a randomized trial, a treatment response, and a safety committee vote
    • A hospital admission, a known dose, a genetic profile, and a published case report
    • An adverse event or other observation, a suspect or interacting product, an identifiable patient, and an identifiable reporter